Sign In
Buy MESO
$14.52
+0 (+0%)
At Close: Jun 03, 2026
NEW YORK, Nov. 11, 2020 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq: MESO; ASX: MSB) today announced that the randomized controlled Phase 3 trial of remestemcel-L in patients with moderate to severe
Rosen, Top Ranked Investor Counsel, Reminds Mesoblast Limited Investors of Important Deadline in Securities Class Action - MESO
07:15pm, Friday, 06'th Nov 2020
New York, New York--(Newsfile Corp. - November 6, 2020) - Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16,
Pomerantz Law Firm Announces the Filing of a Class Action against and Mesoblast Limited Certain Officers - MESO
08:24pm, Friday, 30'th Oct 2020
NEW YORK, Oct. 30, 2020 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Mesoblast Limited ("Mesoblast" or the "Company") (NASDAQ: MESO) and certain of its of
LOS ANGELES, Oct. 30, 2020 /PRNewswire/ -- The Law Offices of Frank R. Cruz reminds investors of the upcoming December 7, 2020 deadline to file a lead plaintiff motion in the class action filed on beh
Update on Remestemcel-L For the Treatment of COVID-19 ARDS and Steroid-Refractory Acute GVHD
06:00am, Thursday, 29'th Oct 2020
Quarterly Activity Report Quarterly Activity Report
New York, New York--(Newsfile Corp. - October 28, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of
NEW YORK, Oct. 28, 2020 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1
New York, New York--(Newsfile Corp. - October 26, 2020) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities
Calithera Terminating Partnership, And Other News: The Good, Bad And Ugly Of Biopharma
07:27am, Wednesday, 09'th Sep 2020
Calithera signals terminating partnership with Incyte. Lexicon reports dosing in Phase 2 clinical study for LX9211.
Mesoblast Before The PDUFA
07:53am, Monday, 31'st Aug 2020
Mesoblast's stem cell therapy candidate has had an outstanding advisory committee meeting where it was voted 9-1. Approval at PDUFA next month is a given.
Mesoblast Limited (MESO) CEO Silviu Itescu on Q4 2020 Results - Earnings Call Transcript
05:27am, Thursday, 27'th Aug 2020
Mesoblast Limited (NASDAQ:MESO) Q4 2020 Earnings Conference Call August 26, 2020 6:00 P.M. ET Company Participants Silviu Itescu - Chief Executive Officer and Managing Director Josh Muntner - Chief Fi
Mesoblast Limited 2020 Q4 - Results - Earnings Call Presentation
02:12am, Thursday, 27'th Aug 2020
The following slide deck was published by Mesoblast Limited in conjunction with their 2020 Q4 earnings call.
Mesoblast Limited Investors: Company Investigated by the Portnoy Law Firm
12:00pm, Wednesday, 19'th Aug 2020
Investors can contact the law firm at no cost to learn more about recovering their lossesLOS ANGELES, Aug. 19, 2020 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Mesoblast Limited ("Mesoblast" or t
NEW YORK, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of Mesoblast Limited
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Mesoblast Limited
